Phase II Study of Pancreatic Adenocarcinoma Signature Stratification for Treatment (PASS-01)
Summary
The purpose of this phase II trial is to evaluate the two standard chemotherapy regimens modified FOLFIRINOX and Gemcitabine and Nab-paclitaxel, in patients with untreated metastatic adenocarcinoma.
General Information
NCT#: NCT04469556
Study ID: PASS-01
Trial Phase: Phase II
Trial Sponsor: University Health Network, Toronto
Therapies Used in This Trial: Nab-paclitaxel, Gemcitabine, FOLFIRINOX